ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
SPRY2	10253	21111454	-	Hypermethylation	-	-	80	157	-	-	Hospital Univesritari Arnau de Vilanova de Lleida and Hospital de Sant Pau; Barcelona; Spain	I (n=108); II (n=15); III (n=22); IV (n=1)	1 (n=43); 2 (n=11); 3 (n=8)	[1] The alterations in sprouty 2 may be involved in endometrial carcinogenesis by controlling cell proliferation. [2] SPRY2 is a good candidate to be tumor suppressor genein EC; because of 3 reasons: (1) SPRY2 is a tumorsuppressor gene in other solid tumors; (2) the 13q31 region;containing the SPRY2 gene; shows frequent deletions in EC;and (3) SPRY2 is a negative regulator of signaling pathways;which are frequently deregulated in EC. [3] The immunohistochemical expression of sprouty 2 was correlated with cellular proliferation (Ki67) and clinicopathologic data. Sprouty 2 promoter methylation was assessed by methylation-specific polymerase chain reaction; with DNA obtained from fresh-frozen samples of endometrial carcinoma and corresponding normal tissues; and correlated with promoter methylation of RAS association domain family-1A (RASSF1A). A highly significant decrease in sprouty 2 immunoexpression was seen in the proliferative phase of normal endometrium (P < .001).	Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma	Human Pathology	42(2):185-93	2011